Martine A. Rothblatt Sells 3,600 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Thursday, June 27th. The shares were sold at an average price of $316.62, for a total value of $1,139,832.00. Following the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $41,160.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

United Therapeutics Trading Up 0.5 %

NASDAQ:UTHR opened at $318.55 on Friday. The firm has a 50-day simple moving average of $274.77 and a 200-day simple moving average of $244.04. United Therapeutics Co. has a one year low of $208.62 and a one year high of $321.80. The firm has a market cap of $14.13 billion, a P/E ratio of 15.06, a P/E/G ratio of 1.39 and a beta of 0.49. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.64 and a current ratio of 3.77.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. The company had revenue of $677.70 million during the quarter, compared to the consensus estimate of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. United Therapeutics’s revenue for the quarter was up 33.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.86 earnings per share. Equities analysts anticipate that United Therapeutics Co. will post 24.73 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Rise Advisors LLC purchased a new position in United Therapeutics in the first quarter valued at about $32,000. GAMMA Investing LLC purchased a new position in shares of United Therapeutics in the 4th quarter worth approximately $43,000. Benjamin F. Edwards & Company Inc. raised its stake in shares of United Therapeutics by 63.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 117 shares in the last quarter. Janiczek Wealth Management LLC lifted its position in United Therapeutics by 21.1% during the first quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock valued at $111,000 after acquiring an additional 84 shares during the last quarter. Finally, Blue Trust Inc. boosted its stake in United Therapeutics by 10.0% in the fourth quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 46 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on UTHR. The Goldman Sachs Group raised their price target on United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. Oppenheimer boosted their target price on shares of United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. Wells Fargo & Company upped their price target on shares of United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a report on Wednesday, June 12th. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 20th. Finally, JPMorgan Chase & Co. upped their target price on shares of United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 21st. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $312.22.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.